Figure 5.
DOR in patients treated with JCAR014 with and without durvalumab. Kaplan-Meier estimates of the DOR according to treatment cohort. P value per log-rank test. The numbers of patients at risk at 10-month intervals are indicated.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.